TIB (tumor infiltrating B-cell) mediated responses, visualized by antibodies recognizing KRAS mutations, have been described in patients with pancreas adenocarcinoma (PDAC) (255), highlighting their clinical utility in anti-tumor immune responses. Here, KRAS is linked to neoplasm.